Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Biogen, Eisai's LEQEMBI IQLIK Now Available in US for Early Alzheimer's Disease

Biogen, Eisai's LEQEMBI IQLIK Now Available in US for Early Alzheimer's Disease

MT newswireMT newswire2026/08/24 12:55
08:55 AM EDT, 08/24/2026 (MT Newswires) -- Biogen (BIIB) and Japanese pharmaceutical company Eisai said Monday that LEQEMBI IQLIK, a once-weekly autoinjector formulation of lecanemab-irmb, is now available in the US for initiation therapy in adults with early Alzheimer's disease. The treatment is indicated for patients with mild cognitive impairment or mild dementia due to Alzheimer's disease. The drug is administered using an autoinjector to provide 500 mg once a week in two consecutive 250 mg injections, with each injection taking about 15 seconds to deliver. LEQEMBI IQLIK is available through the LEQEMBI Specialty Pharmacy Network, the companies said.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Anthropic has not yet gone public, but 20 leveraged ETFs have already "jumped the gun"

More than 20 leveraged ETF products focused on Anthropic have already completed early filings in the United States prior to listing, with issuers including Direxion, ProShares, and GraniteShares. Competition is intensifying even before the IPO. First-mover advantage is critical; after SpaceX went public, out of 14 related products, only one reached assets under management of over 100 million USD. The "winner-takes-all" effect is driving issuers to rush to market.

华尔街见闻•2026/11/19 01:12
Anthropic has not yet gone public, but 20 leveraged ETFs have already "jumped the gun"